UPB ▲ +1.2% - Upstream Bio, Inc. $UPB - Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP Upstream Bio shares rose 1.2% following the company's announcement of pivotal Phase 3 development plans for its drug candidate verekitug in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), signaling progress in two potential market opportunities for the therapy. 01-SEP-2026 07:02 AM ET